Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy ALT?
Source: Benzinga
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.020
Low
12.00
Averages
16.00
High
20.00
Current: 3.020
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Reports Q1 2026 Financial Results and Progress on Pemvidutide
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million, significantly strengthening its financial foundation with a cash balance of approximately $535 million, ensuring funding for the MASH Phase III clinical trial in 2026.
- Clinical Trial Progress: The company plans to initiate the global Phase III clinical trial for MASH, named PERFORMA, in the second half of 2026, having submitted the final study protocol to the FDA, which is expected to support regulatory submissions across multiple regions, showcasing strategic positioning in liver disease treatment.
- Market Demand Analysis: Market research indicates that pemvidutide demonstrates favorable tolerability and efficacy in MASH patients, expected to address the growing unmet medical needs in this area, further solidifying Altimmune's competitive position in the biopharmaceutical market.
- Future Outlook: Altimmune is focused on executing its strategy, with top-line data from the AUD Phase II trial expected next quarter, further advancing the clinical development of pemvidutide and aiming to create long-term value for shareholders.
See More
Altimmune Q1 2026 Earnings Call Insights
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million in gross proceeds, resulting in a cash balance of approximately $535 million as of April 30, which provides the company with sufficient funds to support its clinical programs through the critical data readout in 2029.
- Clinical Trial Progress: The company expects to initiate its global Phase III MASH trial, named PERFORMA, in the second half of this year, with data serving as the basis for regulatory submissions in multiple regions, marking a significant milestone in its global development strategy.
- Financial Performance: In Q1 2026, R&D expenses totaled $16.2 million, G&A expenses were $8.1 million, and the net loss amounted to $22.6 million, or $0.18 per share, indicating financial pressure while advancing clinical development.
- Future Outlook: Altimmune plans to report top-line data from the Phase II trial in alcohol use disorder next quarter and expects to complete enrollment for the RESTORE trial in ALD by Q3 2026, demonstrating positive progress across multiple clinical trials and confidence in future growth.
See More
SureNano Science Develops Next-Gen GLP-1 Therapy GEP-44
- Significant Market Potential: The global GLP-1 market is projected to reach $190 billion by 2035, and SureNano Science aims to capitalize on this rapidly growing market by developing GEP-44, a next-generation triple agonist that enhances its competitiveness in obesity and metabolic disease treatment.
- Innovative Therapy Development: GEP-44 is designed as a patented metabolic therapy to address the limitations of first-generation GLP-1 drugs, targeting GLP-1 alongside peptide YY receptors Y1 and Y2, which may significantly improve patient tolerability and treatment outcomes, thereby facilitating successful FDA approval.
- Positive Preclinical Data: SureNano's preclinical studies indicate that GEP-44 achieves approximately 15% weight loss compared to 9% with traditional drugs, while also avoiding common side effects like nausea and gastrointestinal discomfort, potentially establishing a competitive edge in the future market.
- Delivery Technology Innovation: SureNano is exploring non-injection delivery technologies, including oral and sublingual methods, to enhance patient accessibility and long-term adherence, a strategy that not only improves patient experience but may also create new commercial opportunities in a competitive landscape.
See More
Altimmune Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Beat: Altimmune reported a Q1 GAAP EPS of -$0.18, exceeding expectations by $0.07, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of April 30, 2026, the company had approximately $535 million in cash, cash equivalents, and short-term investments, reflecting the successful completion of a $225 million oversubscribed public offering in April 2026, ensuring ample funding for future growth.
- Market Reaction Analysis: Despite the strong earnings report, market sentiment remains cautious as some analysts downgrade ratings due to uncertainties surrounding the MASH project, which may impact short-term stock performance.
- Future Outlook: Altimmune is contemplating whether it can replicate the stock price surge seen in 2025; while challenges persist, the robust cash flow supports its strategic initiatives, potentially attracting more investor interest.
See More
Altimmune to Announce Q1 Earnings on May 13
- Earnings Announcement Schedule: Altimmune is set to announce its Q1 2023 earnings on May 13 before the market opens, with a consensus EPS estimate of -$0.25, indicating ongoing challenges in profitability.
- Revenue Expectation Analysis: Although revenue estimates stand at $0, EPS estimates have seen four upward revisions and two downward revisions over the last three months, suggesting a divergence in analysts' outlooks that could impact investor confidence.
- Public Offering Dynamics: Altimmune recently priced a $225 million public offering of securities aimed at funding its late-stage clinical trials, a move that may affect its capital structure and future growth trajectory.
- Market Reaction Observation: Despite positive discussions surrounding the MASH promise, analysts have downgraded Altimmune's rating to Hold, reflecting concerns over the high costs associated with operating independently, which may lead to a cautious investor sentiment regarding its future growth potential.
See More
Altimmune to Report Q1 2026 Financial Results on May 13
- Earnings Announcement: Altimmune is set to report its Q1 2026 financial results on May 13, 2026, with management hosting a conference call at 8:30 a.m. ET to discuss the results and provide a business update, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The call will be webcast live on Altimmune's Investor Relations website, and participants must register in advance to receive dial-in numbers and a unique PIN, ensuring investors can easily access the latest information.
- Key Drug Candidate: Altimmune's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), showcasing the company's innovative potential in liver disease treatment.
- Company Overview: As a late clinical-stage biopharmaceutical company, Altimmune focuses on developing therapies for serious liver diseases, indicating its strategic positioning and responsiveness to market demand in the biopharmaceutical industry.
See More
Altimmune Reports Q1 2026 Financial Results and Progress on Pemvidutide
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million, significantly strengthening its financial foundation with a cash balance of approximately $535 million, ensuring funding for the MASH Phase III clinical trial in 2026.
- Clinical Trial Progress: The company plans to initiate the global Phase III clinical trial for MASH, named PERFORMA, in the second half of 2026, having submitted the final study protocol to the FDA, which is expected to support regulatory submissions across multiple regions, showcasing strategic positioning in liver disease treatment.
- Market Demand Analysis: Market research indicates that pemvidutide demonstrates favorable tolerability and efficacy in MASH patients, expected to address the growing unmet medical needs in this area, further solidifying Altimmune's competitive position in the biopharmaceutical market.
- Future Outlook: Altimmune is focused on executing its strategy, with top-line data from the AUD Phase II trial expected next quarter, further advancing the clinical development of pemvidutide and aiming to create long-term value for shareholders.
See More
Altimmune Q1 2026 Earnings Call Insights
- Successful Financing: Altimmune completed an oversubscribed public offering in April, raising $225 million in gross proceeds, resulting in a cash balance of approximately $535 million as of April 30, which provides the company with sufficient funds to support its clinical programs through the critical data readout in 2029.
- Clinical Trial Progress: The company expects to initiate its global Phase III MASH trial, named PERFORMA, in the second half of this year, with data serving as the basis for regulatory submissions in multiple regions, marking a significant milestone in its global development strategy.
- Financial Performance: In Q1 2026, R&D expenses totaled $16.2 million, G&A expenses were $8.1 million, and the net loss amounted to $22.6 million, or $0.18 per share, indicating financial pressure while advancing clinical development.
- Future Outlook: Altimmune plans to report top-line data from the Phase II trial in alcohol use disorder next quarter and expects to complete enrollment for the RESTORE trial in ALD by Q3 2026, demonstrating positive progress across multiple clinical trials and confidence in future growth.
See More
SureNano Science Develops Next-Gen GLP-1 Therapy GEP-44
- Significant Market Potential: The global GLP-1 market is projected to reach $190 billion by 2035, and SureNano Science aims to capitalize on this rapidly growing market by developing GEP-44, a next-generation triple agonist that enhances its competitiveness in obesity and metabolic disease treatment.
- Innovative Therapy Development: GEP-44 is designed as a patented metabolic therapy to address the limitations of first-generation GLP-1 drugs, targeting GLP-1 alongside peptide YY receptors Y1 and Y2, which may significantly improve patient tolerability and treatment outcomes, thereby facilitating successful FDA approval.
- Positive Preclinical Data: SureNano's preclinical studies indicate that GEP-44 achieves approximately 15% weight loss compared to 9% with traditional drugs, while also avoiding common side effects like nausea and gastrointestinal discomfort, potentially establishing a competitive edge in the future market.
- Delivery Technology Innovation: SureNano is exploring non-injection delivery technologies, including oral and sublingual methods, to enhance patient accessibility and long-term adherence, a strategy that not only improves patient experience but may also create new commercial opportunities in a competitive landscape.
See More
Altimmune Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Beat: Altimmune reported a Q1 GAAP EPS of -$0.18, exceeding expectations by $0.07, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of April 30, 2026, the company had approximately $535 million in cash, cash equivalents, and short-term investments, reflecting the successful completion of a $225 million oversubscribed public offering in April 2026, ensuring ample funding for future growth.
- Market Reaction Analysis: Despite the strong earnings report, market sentiment remains cautious as some analysts downgrade ratings due to uncertainties surrounding the MASH project, which may impact short-term stock performance.
- Future Outlook: Altimmune is contemplating whether it can replicate the stock price surge seen in 2025; while challenges persist, the robust cash flow supports its strategic initiatives, potentially attracting more investor interest.
See More
Altimmune to Announce Q1 Earnings on May 13
- Earnings Announcement Schedule: Altimmune is set to announce its Q1 2023 earnings on May 13 before the market opens, with a consensus EPS estimate of -$0.25, indicating ongoing challenges in profitability.
- Revenue Expectation Analysis: Although revenue estimates stand at $0, EPS estimates have seen four upward revisions and two downward revisions over the last three months, suggesting a divergence in analysts' outlooks that could impact investor confidence.
- Public Offering Dynamics: Altimmune recently priced a $225 million public offering of securities aimed at funding its late-stage clinical trials, a move that may affect its capital structure and future growth trajectory.
- Market Reaction Observation: Despite positive discussions surrounding the MASH promise, analysts have downgraded Altimmune's rating to Hold, reflecting concerns over the high costs associated with operating independently, which may lead to a cautious investor sentiment regarding its future growth potential.
See More
Altimmune to Report Q1 2026 Financial Results on May 13
- Earnings Announcement: Altimmune is set to report its Q1 2026 financial results on May 13, 2026, with management hosting a conference call at 8:30 a.m. ET to discuss the results and provide a business update, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The call will be webcast live on Altimmune's Investor Relations website, and participants must register in advance to receive dial-in numbers and a unique PIN, ensuring investors can easily access the latest information.
- Key Drug Candidate: Altimmune's lead candidate, pemvidutide, is a unique dual-action therapy targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD), showcasing the company's innovative potential in liver disease treatment.
- Company Overview: As a late clinical-stage biopharmaceutical company, Altimmune focuses on developing therapies for serious liver diseases, indicating its strategic positioning and responsiveness to market demand in the biopharmaceutical industry.
See More
